167 related articles for article (PubMed ID: 21393428)
21. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
Chen KF; Chen HL; Shiau CW; Liu CY; Chu PY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Br J Pharmacol; 2013 Feb; 168(3):658-72. PubMed ID: 22978563
[TBL] [Abstract][Full Text] [Related]
23. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
[TBL] [Abstract][Full Text] [Related]
24. Cucurbitacin B reverses multidrug resistance by targeting CIP2A to reactivate protein phosphatase 2A in MCF-7/adriamycin cells.
Cai F; Zhang L; Xiao X; Duan C; Huang Q; Fan C; Li J; Liu X; Li S; Liu Y
Oncol Rep; 2016 Aug; 36(2):1180-6. PubMed ID: 27350399
[TBL] [Abstract][Full Text] [Related]
25. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
[TBL] [Abstract][Full Text] [Related]
26. TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway.
Chao TT; Wang CY; Lai CC; Chen YL; Tsai YT; Chen PT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
J Pharmacol Exp Ther; 2014 Nov; 351(2):352-8. PubMed ID: 25187431
[TBL] [Abstract][Full Text] [Related]
27. Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line.
Saafan H; Alahdab A; Michelet R; Gohlke L; Ziemann J; Holdenrieder S; McLaughlin KM; Wass MN; Cinatl J; Michaelis M; Kloft C; Ritter CA
Cells; 2021 Mar; 10(4):. PubMed ID: 33804833
[TBL] [Abstract][Full Text] [Related]
28. Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A.
Chao TT; Wang CY; Chen YL; Lai CC; Chang FY; Tsai YT; Chao CH; Shiau CW; Huang YC; Yu CJ; Chen KF
Oncotarget; 2015 Feb; 6(4):2164-79. PubMed ID: 25537503
[TBL] [Abstract][Full Text] [Related]
29. 2,5-Dimethyl Celecoxib Inhibits Proliferation and Cell Cycle and Induces Apoptosis in Glioblastoma by Suppressing CIP2A/PP2A/Akt Signaling Axis.
Gao D; Nyalali AMK; Hou Y; Xu Y; Zhou J; Zhao W; Huang B; Li F
J Mol Neurosci; 2021 Aug; 71(8):1703-1713. PubMed ID: 33400072
[TBL] [Abstract][Full Text] [Related]
30. CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.
Gao F; Wang X; Chen S; Xu T; Wang X; Shen Y; Dong F; Zhong S; Shen Z
Oncol Rep; 2018 Nov; 40(5):2445-2454. PubMed ID: 30106121
[TBL] [Abstract][Full Text] [Related]
31. Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway.
Inoue T; Shiraki K; Fuke H; Yamanaka Y; Miyashita K; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Anticancer Drugs; 2006 Mar; 17(3):261-8. PubMed ID: 16520654
[TBL] [Abstract][Full Text] [Related]
32. Micropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression.
Guo B; Wu S; Zhu X; Zhang L; Deng J; Li F; Wang Y; Zhang S; Wu R; Lu J; Zhou Y
EMBO J; 2020 Jan; 39(1):e102190. PubMed ID: 31755573
[TBL] [Abstract][Full Text] [Related]
33. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim.
Nikrad M; Johnson T; Puthalalath H; Coultas L; Adams J; Kraft AS
Mol Cancer Ther; 2005 Mar; 4(3):443-9. PubMed ID: 15767553
[TBL] [Abstract][Full Text] [Related]
34. Cucurbitacin B induces inhibitory effects via CIP2A/PP2A/Akt pathway in glioblastoma multiforme.
Qin S; Li J; Si Y; He Z; Zhang T; Wang D; Liu X; Guo Y; Zhang L; Li S; Li Q; Liu Y
Mol Carcinog; 2018 Jun; 57(6):687-699. PubMed ID: 29393542
[TBL] [Abstract][Full Text] [Related]
35. (+)-Cyanidan-3-ol inhibits epidermoid squamous cell carcinoma growth via inhibiting AKT/mTOR signaling through modulating CIP2A-PP2A axis.
Monga J; Suthar SK; Rohila D; Joseph A; Chauhan CS; Sharma M
Phytomedicine; 2022 Jul; 101():154116. PubMed ID: 35525235
[TBL] [Abstract][Full Text] [Related]
36. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
Luster TA; Carrell JA; McCormick K; Sun D; Humphreys R
Mol Cancer Ther; 2009 Feb; 8(2):292-302. PubMed ID: 19174554
[TBL] [Abstract][Full Text] [Related]
37. Euxanthone suppresses tumor growth and metastasis in colorectal cancer via targeting CIP2A/PP2A pathway.
Wang N; Zhou F; Guo J; Zhu H; Luo S; Cao J
Life Sci; 2018 Sep; 209():498-506. PubMed ID: 30144452
[TBL] [Abstract][Full Text] [Related]
38. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.
Kim MO; Choe MH; Yoon YN; Ahn J; Yoo M; Jung KY; An S; Hwang SG; Oh JS; Kim JS
Biochem Pharmacol; 2017 Nov; 144():78-89. PubMed ID: 28813646
[TBL] [Abstract][Full Text] [Related]
39. Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism.
Wang HW; Yang SH; Huang GD; Lin JK; Chen WS; Jiang JK; Lan YT; Lin CC; Hwang WL; Tzeng CH; Li AF; Yen CC; Teng HW
J Cancer Res Clin Oncol; 2014 Apr; 140(4):561-71. PubMed ID: 24493623
[TBL] [Abstract][Full Text] [Related]
40. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.
Zhu H; Guo W; Zhang L; Wu S; Teraishi F; Davis JJ; Dong F; Fang B
Cancer Biol Ther; 2005 Jul; 4(7):781-6. PubMed ID: 16082182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
